MYCOF News and Press, New Age Brands From 01/20/21

Miller Thomson LLP requests that their press release NewsItemId: 20210120005543 “Mydecine Innovations Group Upsizes Previously Announced Bought Deal” be killed. The release was issued by Miller Thomson LLP without prior authorization from Mydecine Innovations G...

Miller Thomson LLP requests that their press release NewsItemId: 20210120005542 “Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units” be killed. The release was issued by Miller Thomson LLP without prior authorization from Mydecine I...

Mydecine Innovations ([[MYCOF]] +2.1%) enters into an agreement with Canaccord Genuity, pursuant to which Canaccord agrees to purchase, on a bought deal basis an aggregate of 20M units of the company at a price of C$0.50 per unit; gross proceeds of C$10M.Underwriter's option to purchase ...

Mydecine Innovations Group Upsizes Previously Announced Bought Deal Canada NewsWire /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / DENVER , Jan. 14, 2021 /CNW/ - Mydecine Innovations Group ...

Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units Canada NewsWire /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / DENVER , Jan. 14, 2021 /CNW/ - Mydecine Innova...

KCSA Strategic Communications to Host Inaugural KCSA Psychedelics Investor Conference on January 26-27, 2021 Featuring presentations by eminent psychedelics companies and industry leaders including keynote speakers, Rick Doblin, MAPS and Amy Emerson, MAPS Public Benefit Corporat...

DENVER, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-so...

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Mydecine Innovations Group Shares Intellectual Property Update.” Mydecine Innovations Group (OTC: MYCOF) (CSE: MYCO) , an emerging biopharma and...

FinancialBuzz.com News Commentary New York, NY (1/7/2021) – Among the popular fields of study for biotech companies in recent years are gene editing, tissue engineering and regeneration, nanobiotechnology and others. In addition, new segments under the biotech umbrella are consta...

Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream us...